Athira Pharma logo
Athira Pharma ATHA

Quarterly report 2025-Q3
added 11-06-2025

report update icon

Athira Pharma Accounts Payables 2011-2026 | ATHA

Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.
Main types of accounts payable
Type of liabilityExample
To suppliers and contractorsGoods received but not yet paid for
Taxes and feesVAT, income tax, etc., not paid on time
SalariesEmployee wages not paid
To budgetsInsurance contributions to funds not paid
To foundersFounders provided borrowed funds
To banksOverdue loan payments
OtherFines, penalties, forfeits, customer prepayments, etc.

Impact on the company's financial performance
  1. Liquidity and solvency
    Accounts payable are part of short-term liabilities, so they affect liquidity ratios
  2. Financial stability
    The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence
  3. Capital turnover
    Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals)
  4. Risks and reputation
    Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated

Annual Accounts Payables Athira Pharma

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
319 K 129 K 2.5 M 567 K 1.16 M - - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
2.5 M 129 K 935 K

Quarterly Accounts Payables Athira Pharma

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
266 K 171 K 867 K 319 K 388 K 475 K 681 K 129 K 1.71 M 612 K 892 K 2.5 M 751 K 605 K 1.43 M 567 K 959 K 1.17 M 1.69 M 1.16 M 1.16 M 1.16 M 1.16 M 421 K 421 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
2.5 M 129 K 866 K

Accounts Payables of other stocks in the Biotechnology industry

Issuer Accounts Payables Price % 24h Market Cap Country
Acer Therapeutics Acer Therapeutics
ACER
3.81 M - 2.71 % $ 14 M usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
8.13 M - -15.15 % $ 60.3 M britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
1.61 M - - $ 86.2 M usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
45.7 M $ 80.34 - $ 1.55 B usaUSA
Acasti Pharma Acasti Pharma
ACST
601 K - 4.01 % $ 150 M canadaCanada
Aptorum Group Limited Aptorum Group Limited
APM
3.24 M $ 0.84 1.96 % $ 4.58 M chinaChina
I-Mab I-Mab
IMAB
570 M - - $ 866 M chinaChina
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
2.91 M - - $ 26.5 M usaUSA
Adagene Adagene
ADAG
4.24 M $ 2.67 - $ 150 M chinaChina
AlloVir AlloVir
ALVR
247 K - 4.14 % $ 49.1 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
750 K - -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
1.58 M - - $ 10.1 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
3.46 M - 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
13.4 M - -24.86 % $ 820 K usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
9.03 M - - $ 3.67 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
677 K - - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
14.6 M $ 1.5 - $ 281 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
1.26 M - -45.71 % $ 1.2 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
6.52 M - -0.23 % $ 916 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
1.03 M - 3.16 % $ 1.9 M usaUSA
Aptinyx Aptinyx
APTX
724 K - -39.0 % $ 4.57 M usaUSA
Aravive Aravive
ARAV
8.76 M - -13.39 % $ 1.45 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
4.55 M $ 2.44 - $ 2.85 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
13.3 M - -6.81 % $ 3.04 B usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
2.31 M - 17.91 % $ 11.1 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
1.41 M - -10.17 % $ 12.2 K usaUSA
Athersys Athersys
ATHX
9.16 M - 3.77 % $ 22.4 M usaUSA
Akouos Akouos
AKUS
1.28 M - 0.23 % $ 488 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
155 K - -52.27 % $ 4.45 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
561 K $ 4.22 - $ 9.18 B israelIsrael
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
1.97 M $ 1.46 - $ 373 M britainBritain
Compugen Ltd. Compugen Ltd.
CGEN
1.84 M $ 1.71 - $ 153 M israelIsrael
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
153 M $ 14.52 - $ 4.49 B usaUSA
AVROBIO AVROBIO
AVRO
27 K - 1083.1 % $ 745 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
4.29 M - - $ 2.17 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
4.08 M - - $ 7.46 M israelIsrael